A comparison of two low-intensity transplant regimens for the treatment of adults with acute lymphoblastic leukaemia (ALL) over the age of 40 years (ALL-RIC trial)

Submission date	Recruitment status No longer recruiting	Prospectively registered		
08/01/2019		[X] Protocol		
Registration date	Overall study status Ongoing Condition category Cancer	Statistical analysis plan		
25/01/2019		ResultsIndividual participant data		
Last Edited				
06/06/2024		Record updated in last year		

Plain English summary of protocol

Available at: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-treatments-for-acute-lymphoblastic-leukaemia-all-ric

Contact information

Type(s)

Scientific

Contact name

Dr Andrea Hodgkinson

Contact details

CRCTU, Centre for Clinical Haematology Queen Elizabeth Hospital Edgbaston Birmingham United Kingdom B15 2TH

a.hodgkinson@bham.ac.uk

Type(s)

Public

Contact name

Mr Nicholas Martin

Contact details

CRCTU, Centre for Clinical Haematology Queen Elizabeth Hospital, Edgbaston Birmingham United Kingdom B15 2TH +44 (0)121 371 7856 ALL-RIC@trials.bham.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2017-004800-23

ClinicalTrials.gov (NCT)

NCT03821610

Protocol serial number

38207; RG 17 241

Study information

Scientific Title

A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission

Acronym

ALL-RIC

Study objectives

The UKALL XIV trial has prospectively studied reduced intensity conditioning (RIC) transplants in adults with acute lymphoblastic leukaemia (ALL) in first remission over 40 years of age. Given this group had 15-20% survival in the previous UKALL XII trial, the 56% 2 year disease-free-survival (DFS) is encouraging. However, relapse at 2 years is high at 27%, especially in patients who come to transplant minimal residual disease (MRD) positive. Previous studies suggested that total body irradiation (TBI) conditioning in patients who received full intensity or RIC transplants reduced treatment failure (OR 1.4). The trialists propose to compare the two conditioning regimens and postulate that total body irradiation (TBI) 8Gy and cyclophosphamide 100mg/kg will be well tolerated and will reduce relapse. Experience from the German group with 8Gy TBI and in the SCOT trial suggests that this regimen is well tolerated with minimal extramedullary toxicity and low transplant related mortality (TRM).

Ethics approval required

Old ethics approval format

Ethics approval(s)

East Midlands - Leicester Central Research Ethics Committee, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, Tel: +44 (0)207 104 8098; Email: nrescommittee.eastmidlands-leicestercentral@nhs.net, 12/06/2018, ref: 18/EM/0112

Study design

Randomised; Interventional; Design type: Treatment, Drug, Radiotherapy

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute lymphoblastic leukaemia

Interventions

This is a two-arm phase II, multicentre, randomised clinical trial comparing the outcome of patients transplanted using a TBI and cyclophosphamide allograft with patients transplanted with a FMA conditioning regimen. Patients with ALL who fulfil the eligibility criteria will be invited to participate in the trial across UK centres performing allogeneic SCT.

Patients will be randomised to treatment based on a minimisation algorithm prepared at the Cancer Research UK Clinical Trials Unit (CRCTU). Minimisation will be based upon age (>55; <55 years) and by donor type (sibling; unrelated).

Active Comparator: Fludarabine / Melphalan / Alemtuzumab

Day -7: Fludarabine 30 mg/m2 od IV

Day -6: Fludarabine 30 mg/m2 od IV

Day -5: Fludarabine 30 mg/m2 od IV

Day -4: Fludarabine 30 mg/m2 od IV

Day -3: Fludarabine 30 mg/m2 od IV

Day -2: Melphalan 140 mg/m2 od IV, Alemtuzumab 30 mg od IV (unrelated transplants only)

Day -1: Alemtuzumab 30 mg od IV

Day 0: Infusion of sibling or unrelated donor peripheral blood stem cells

Experimental: Cyclophosphamide / TBI (8 Gy)

Day -6: Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV

Day -5: Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV

Day -4: Rest

Day -3: TBI (2 Gy) bd

Day -2: TBI (2 Gy) bd, Alemtuzumab 30 mg od IV (unrelated transplants only)

Day -1: Alemtuzumab 30 mg od IV

Day 0: Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow

Patients will be followed-up for a minimum of 5 years from the date of randomisation.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Fludarabine, melphalan, alemtuzumab, cyclophosphamide, mesna

Primary outcome(s)

Disease Free Survival (DFS) defined as time from randomisation to the first of relapse or death from any cause. Patients who are still alive and progression free at the end of the trial will be censored at the date they were last known to be alive. Bone marrow assessments carried out to assess disease status at baseline, Day 100, Month 6/9/12/15/18/21/24/30/36

Key secondary outcome(s))

- 1. Overall Survival defined as time from randomisation to date of death from any cause. Patients who are alive at the end of the trial will be censored at their date last known to be alive. Information will be captured on a Death Form Case Report Form (CRF).
- 2. Cumulative Incidence of Relapse (CIR) defined as time from randomisation to the date of relapse. Patients who die without relapse will be treated as a competing risk and patients who are alive and relapse free at the end of the trial will be censored as their date last seen
- 3. Non Relapse Mortality (NRM) defined as time from randomisation to death from any cause that occurred without relapse. Patients who relapse will be treated as a competing risk and patients who are still alive and relapse free at the end of the trial will be censored at their date last known to be alive. Incidence of Grade 2-4 acute GvHD within 100 days of transplant. GvHD should be assessed continuously throughout the trial according to Glucksberg Criteria (see Appendix 4 of protocol)
- 4. Incidence of chronic GvHD of any grade at 2 years. See above.
- 5. Occurrence and severity of VOD in the first 100 days, captured on a specific Veno-Occlusive Disease CRF (which is based on the new EBMT criteria for SOS/VOD diagnosis in adults). All post-transplant events of VOD should be reported as a SAE irrespective of how long after IMP has been administered.
- 6. Duration of hospitalisation recorded on Hospitalisation Form CRF between start of conditioning regimen and 1 year post transplantation
- 7. Quality of life assessed using SF36 and FACT-BMT at baseline, 3 months, 12 months and years 2, 3, 4 and 5
- 8. Full donor chimerism recorded at day 100 follow up
- 9. Occurrence and severity of TBI-related symptomatic pulmonary toxicity in the first 12 months. Assessed using: Forced Expiratory Volume (FEV) 1 (%), Forced Vital Capacity (FVC) (%), % of predicted Peak Expiratory Flow Rate (PEFR), corrected for HL (%), Single Breath diffusing capacity of the lungs for carbon monoxide (DLCO) (%)

Exploratory outcome measures:

- 1. Correlation of multi-lineage chimerism and relapse
- 2. Correlation of MRD with relapse. There is a specific MRD CRF Cumulative incidence of relapse will be assessed by both MRD and multi-lineage chimerism using cumulative incidence curves and multivariable cox models. Analysis will be conducted when patients have been followed up for 2 years

Completion date

22/11/2027

Eligibility

Key inclusion criteria

Patients with morphologically documented ALL who meet the following criteria;

1. Patients between the ages of 40-65 years. NB: Patients under the age of 40 who are

considered unsuitable for a myeloablative transplant may enrol onto the trial following discussion with the CI via the Trials Office

- 2. Patients with ALL in first CR
- 3. Availability of a human leukocyte antigen (HLA) identical sibling or suitable matched unrelated donor (suitable matched defined as no greater than a single allele mismatch at HLA A, B, C or DR β 1). A single allele mismatch is permitted if there are adverse cytogenetics or MRD positivity at any timepoint
- 4. Patients considered suitable to undergo a RIC allogeneic SCT as clinically judged by the Local Investigator including:
- 4.1. Adequate hepatic and renal function as determined by full blood count and biochemistry assessment
- 4.2. Resolution of any toxic effects of prior therapy (including radiotherapy, chemotherapy or surgical procedures). Patients with bone marrow suppression following therapy may enter the trial
- 4.3. Patients with abnormal cardiac and/or pulmonary function must be considered fit for allogeneic SCT including 8Gy of TBI at the time of randomisation.
- 5. Patients with an ECOG performance status 0,1 or 2
- 6. Female of and male patients of reproductive potential (i.e. not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of admission for transplant conditioning therapy until 12 months after transplant
- 7. Patients have given written informed consent
- 8. Patients willing and able to comply with scheduled study visits and laboratory tests

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

102

Key exclusion criteria

- 1. Patients with contraindications to receiving RIC allogeneic SCT
- 2. Female patients who are pregnant or breastfeeding. All women of childbearing potential (WOCBP) must have a negative pregnancy test before commencing treatment
- 3. Adults of reproductive potential not willing to use appropriate, effective, contraception during the specified period
- 4. Patients with renal or hepatic impairment as clinically judged by Local Investigator
- 5. Patients with active infection, HIV-positive or chronic active Hep-A or -C
- 6. Patients with concurrent active malignancy. Patients with a previous history of malignancy can be included if that malignancy is considered to be at a low risk of recurrence

Date of first enrolment

22/11/2018

Date of final enrolment 22/11/2022

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre
NHS Greater Glasgow and Clyde
Department of Haematology
1053 Great Western Road
Glasgow
United Kingdom
G12 0YN

Study participating centre King's College Hospital

Denmark Hill Brixton London United Kingdom SE5 9RS

Study participating centre Leeds Teaching Hospitals NHS Trust

St. James's University Hospital Beckett Street Leeds United Kingdom LS9 7TF

Study participating centre
Central Manchester University Hospitals NHS Foundation Trust
Trust Headquarters
Cobbett House

Oxford Road Manchester United Kingdom M13 9WL

Study participating centre The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Freeman Hospital Freeman Road High Heaton Newcastle-Upon-Tyne United Kingdom NE7 7DN

Study participating centre Oxford University Hospitals NHS Foundation Trust

John Radcliffe Hospital Headley Way Headington Oxford United Kingdom OX3 9DU

Study participating centre

University Hospitals Birmingham NHS Foundation Trust

Trust HQ, PO Box 9551 Queen Elizabeth Medical Centre Edgbaston Birmingham United Kingdom B15 2TH

Study participating centre Barts Health NHS Trust

The Royal London Hospital Whitechapel London United Kingdom E1 1BB

Study participating centre

University Hospitals Bristol NHS Foundation Trust

Marlborough Street Bristol United Kingdom BS1 3NU

Study participating centre University College London Hospitals NHS Foundation Trust

250 Euston Road London United Kingdom NW1 2PG

Study participating centre Cambridge University Hospitals NHS Foundation Trust

Addenbrookes Hospital Hills Road Cambridge United Kingdom CB2 0QQ

Study participating centre Cardiff and Vale University Health Board

University Hospital of Wales Heath Park Cardiff United Kingdom CF14 4XW

Study participating centre The Christie NHS Foundation Trust

550 Wilmslow Road Withington Manchester United Kingdom M20 4BX

Study participating centre Imperial College Healthcare NHS Trust

St Marys Hospital Praed Street London United Kingdom W2 1NY

Study participating centre Heart of England NHS Foundation Trust

Birmingham Heartlands Hospital Bordesley Green East Birmingham United Kingdom B9 5ST

Study participating centre University Hospitals of Leicester NHS Trust

Leicester Royal Infirmary Infirmary Square Leicester United Kingdom LE1 5WW

Study participating centre The Clatterbridge Cancer Centre NHS Foundation Trust

Clatterbridge Road Bebington Liverpool United Kingdom CH63 4JY

Study participating centre Nottingham University Hospitals NHS Trust

Trust Headquarters Queens Medical Centre Derby Road Nottingham United Kingdom NG7 2UH

Study participating centre Plymouth Hospitals NHS TrustDerriford Hospital

Derriford Road

Plymouth United Kingdom PL6 8DH

Study participating centre The Royal Marsden NHS Foundation Trust

Fulham Road London United Kingdom SW3 6JJ

Study participating centre Sheffield Teaching Hospitals NHS Foundation Trust

Northern General Hospital Herries Road Sheffield United Kingdom S5 7AU

Study participating centre

University Hospital Southampton NHS Foundation Trust

Mailpoint 18
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Sponsor information

Organisation

University of Birmingham

ROR

https://ror.org/03angcq70

Funder(s)

Funder type

Funder Name

IMPACT Partnership - Leuka, Anthony Nolan, BSBMT

Results and Publications

Individual participant data (IPD) sharing plan

Trial data will be made available through the EU portal at the end of the trial.

IPD sharing plan summary

Stored in repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		01/06/2023	02/06/2023	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes